ABSTRACT
candidemia, candidiasis
CANDIDEMIA, CANDIDIASIS
Trial Registration: NCT04148287.The authors declare a conflict of interest. Jose A. Vazquez received grant support from Cidara, Scynexis and was a consultant for Cidara, Scynexis, F2G, Amplyx. Michael R. Hodges, Eric Ople, Pamela Wedel were employees of Amplyx (now a Pfizer Inc subsidiary). Michael R. Hodges was previously an employee of Pfizer and holds Pfizer stock. Paul A. Bien and Margaret Tawadrous are employees of Pfizer and hold Pfizer stock. Iwona Oborska was a consultant for Amplyx, previously a Pfizer employee, and Pfizer shareholder. Fathima Paruk has served on the speaker bureaus for Thermofischer Scientific, Pfizer, Biomerieux, MSD and Dr Reddy's. Peter G. Pappas received grant support from Astellas, Gilead, Mayne, Cidara, Scynexis and provided advisory and consultancy services to Amplyx, Mayne, Scynexis. Kenneth Boffard has no conflicts of interest to declare.Fosmanogepix (FMGX), a novel antifungal available in intravenous (IV) and oral formulations, has broad-spectrum activity against pathogenic yeasts and molds, including fungi resistant to standard of care antifungals. This multicenter, open-label, single-arm study evaluated FMGX safety and efficacy for treatment of candidemia and/or invasive candidiasis caused by 